This Biotech Thinks It's Cheap

Amgen (Nasdaq: AMGN  ) thinks its investors aren't valuing the company properly. It's offering to repurchase $5 billion worth of stock -- about 10% of its value -- and even willing to borrow the cash to get it done.

The Dutch auction allows investors to name their price between $54 and $60 that they're willing to sell their shares for. Once all the tender offers are in, Amgen will start at the lowest price and count up until it reaches a price that would allow it to repurchase $5 billion worth of shares. Shares tendered above that price will be retained by the investor, and those tendered for the lower prices will be repurchased by Amgen at the price required to repurchase $5 billion in shares.

Thus, you could tender your shares at $54 and end up selling them at $60 if that's the price required to get enough shares. Conversely, you could tender at $55 and not end up selling your shares if enough investors were willing to sell for $54.99 or less.

Investors have a complex decision to make. If you think shares are overvalued at a price between $54 and $60, tendering the shares is certainly an option. Selling on the open market is another option if the price is fairly close to the $60 ceiling that Amgen is willing to pay. If neither of those works, you could always sell a covered call, generating cash with the possibility of selling at a higher price.

But it might make most sense to just hold onto your shares. Retiring shares -- even if it requires taking on debt -- looks like a good financial move for shareholders who stay. Amgen is trading at 10 times its free cash flow over the past 12 months. As long as the company pays less than 10% interest on the cash it borrows to fund the share repurchase, it should be able to decrease its valuation ratio by retiring shares. Considering the cost of corporate borrowing recently, that shouldn't be too difficult.

While it looks like Amgen is making a good financial move with the buyback, one has to wonder whether repurchasing shares will provide a better long-term return for investors than buying a development-stage drugmaker or five. With $5 billion, Amgen could purchase Exelixis (Nasdaq: EXEL  ) , Keryx Biopharmaceuticals (Nasdaq: KERX ), Aeterna Zentaris (Nasdaq: AEZS  ) , Dendreon (Nasdaq: DNDN  ) , and Seattle Genetics (Nasdaq: SGEN  ) , even factoring in a 25% premium for the companies. Amgen's shares are cheap, but it looks like it's gotten a little conservative in its old age. Investors interested in swinging for the fence might as well tender their shares.

Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Dendreon and Exelixis. Motley Fool newsletter services have recommended buying shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 08, 2011, at 8:36 PM, gregandmelinda wrote:

    EXEL will be the bio stock of the decade. It is a super star in the making as your newsletter state. Carbo will blow the doors open on all types of cancers.

Add your comment.

DocumentId: 1586091, ~/Articles/ArticleHandler.aspx, 4/16/2014 7:26:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement